Methods for the treatment of tissue lesions with CCR2 agonists

US11406686B2 · kind B2 · utility

Assignees

• INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR
• Sorbonne Universite · FR
• UNIVERSITE DE PARIS DESCARTES · FR
• ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS (APHP) · FR

Inventors

• Selim Aractingi · Paris, FR
• Mathieu Catela · Paris, FR
• Dany Nassar · Paris, FR
• Zhe Wang · Xiangtan City, CN

Key dates

• Filing date: May 2, 2017
• Grant date: Aug 9, 2022
• Expiry date: Jul 6, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2310/16
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to methods and pharmaceutical compositions for the treatment of tissue lesions. The inventors showed that CCR2 is expressed on FMCs, especially on a subpopulation of progenitor cells, that they call “fetal myeloid progenitor cells” (FMPCs), and mediates the recruitment of these cells to maternal wound tissue. Moreover, the inventors reported that recruited FMCs/FMPCs improve maternal skin wound healing by organizing blood vessel endothelium and secreting pro-angiogenesis peptides, particularly chemokine CXCL1, to enhance angiogenesis in wound. In particular, the present invention relates to CCR2 agonists for use in the treatment of tissue lesions in a subject in need thereof.